The NF-κB pathway has been reported to be especially relevant in inflammatory cancers, such as gastric and pancreatic cancers, where CBP/p300 inhibitors could potentially reduce NF-κB activity and suppress tumor-promoting inflammation. The gene discussed is NFKB1; the disease is neoplasm.